Healthcare

https://techpapersworld.com/wp-content/uploads/2024/12/Meaningful-Insights-Biotech-Analytics-1280x720.jpg

HealthcareMeaningful Insights Biotech Analytics (MiBA) and Guardant Health Announce Strategic Partnership to Optimize Use of Biomarker Testing and Data Analytics to Improve Cancer Care

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and Meaningful Insights Biotech Analytics (MiBA), an innovative healthcare technology company, today announced a unique partnership aimed at optimizing the use of biomarker testing and data analytics to advance precision medicine in patient care throughout the MiBA Network. “This collaboration with Guardant Health is an innovative approach to precision oncology. By leveraging our technology and data insights, we can enhance understanding and accessibility of genomic...

by PRNewswire

https://techpapersworld.com/wp-content/uploads/2024/12/Fangzhou-Inc.-and-Bristol-Myers-1280x720.jpg

HealthcareFangzhou Inc. and Bristol Myers Squibb China Join Forces on a Strategic Alliance to Advance Internet Healthcare

Fangzhou Inc. (“Fangzhou” or the “Company”) (06086.HK), a pioneer in Internet healthcare solutions, announced a strategic alliance with Bristol Myers Squibb (“BMS”) China on December 16th. The partnership was officially formalized with the signing of a collaboration agreement by Dr. Xie Fangmin, founder, chairman, and CEO of Fangzhou, and Mr. Wen Yizhong, the head of the Innovative Medicines Division at BMS China and General Manager for BMS Hong Kong. This strategic alliance aims to drive innovation in Internet healthcare...

by PRNewswire

https://techpapersworld.com/wp-content/uploads/2024/12/BioArctic-announces-global-license-agreement-1280x720.jpg

HealthcareBioArctic announces global license agreement with Bristol Myers Squibb for BioArctic’s PyroGlutamate-amyloid-beta antibody program

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that it has entered into a global exclusive license agreement with Bristol Myers Squibb (NYSE: BMY) for BioArctic’s PyroGlutamate-amyloid-beta (PyroGlu-Aβ) antibody program, including BAN1503 and BAN2803, whereof the latter includes BioArctic’s BrainTransporter™ technology. As part of the agreement, BioArctic will receive a USD 100 million upfront payment and up to USD 1.25 billion in milestone payments. BioArctic is also entitled to tiered low double-digit royalties on global product sales. Under the agreement, Bristol Myers Squibb will become...

by PRNewswire

https://techpapersworld.com/wp-content/uploads/2024/12/Foothill-Regional-Medical-Center-1280x720.jpg

HealthcareFoothill Regional Medical Center Infection Control Expert Receives Top National Honor

Shahbaz Salehi, MPH, MSHIA, director, infection control, at Foothill Regional Medical Center, has been named the 2024 Educator of the Year by Infection Control Today, a national leader in infection control. Orange County’s Shahbaz Salehi Named Infection Control Today’s 2024 Educator of the Year Infection Control Today 2024 Educator of the Year, Shahbaz Salehi, Foothill Regional Medical Center “The 2024 Infection Control Today Educator of the Year award recognizes an individual who has demonstrated exceptional passion and dedication to educating others, empowering...

by PRNewswire

https://techpapersworld.com/wp-content/uploads/2024/12/IDEAYA-Announces-Development--1280x720.jpg

HealthcareIDEAYA Announces Development Candidate Nomination of IDE251, a Potential First-in-Class KAT6/7 Dual Inhibitor Targeting 8p11 Amplification Tumors in Breast and Lung Cancers

IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced the development candidate nomination of IDE251, a potential first-in-class KAT6/7 dual inhibitor. “We are pleased to announce the nomination of IDE251 as our third development candidate this quarter and 8th development candidate in our precision medicine oncology pipeline. IDE251 has a potential first-in-class product profile and selectively inhibits two epigenetic modulators, KAT6 and KAT7, and based...

by business wire

https://techpapersworld.com/wp-content/uploads/2024/12/SINOVAC-Initiated-a-Phase-III-Clinical-1280x720.jpg

HealthcareSINOVAC Initiated a Phase III Clinical Trial on Bivalent Vaccine Against Hand Foot and Mouth Disease (HFMD)

Sinovac Biotech Ltd. (“SINOVAC” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today kicked off the enrollment for a Phase III clinical trial on a vaccine candidate to prevent HFMD caused by both Enterovirus 71 (EV71) and Coxsackievirus 16 (CA16). Notably, no multivalent vaccines against HFMD have yet been approved for marketing worldwide. The Phase III clinical trial is designed to be a multicenter, randomized, double-blind, controlled trial to evaluate...

by PRNewswire

https://techpapersworld.com/wp-content/uploads/2024/12/Salipro-Biotech-Expands-Global-1280x720.jpg

HealthcareSalipro Biotech Expands Global Intellectual Property Portfolio with Granted Patents in Australia and Singapore

Salipro Biotech AB, a Swedish biotechnology company focused on advancing drug discovery for challenging drug targets, today announced the issuance of granted patents in both Singapore and Australia for its Salipro® platform technology, a novel and proprietary method for directly isolating and purifying native membrane proteins, which are important targets for many therapeutic drugs. The Salipro® platform enables entirely novel drug discovery programs, including antibody discovery, small molecule drug screening and structure-based drug design. The patents, entitled “Production of...

by PRNewswire

https://techpapersworld.com/wp-content/uploads/2024/12/AC-Health-makes-critical-HIV-1280x720.jpg

HealthcareAC Health makes critical HIV care more accessible to Filipinos with USAID support

Ayala Healthcare Holdings, Inc. (AC Health), in partnership with the U.S. Agency for International Development (USAID), is leading the private sector’s efforts to fight the HIV epidemic in the Philippines by improving access to stigma-free care and lifesaving services. The partnership was sealed in time for World AIDS Day, whose theme “Collective Action: Sustain and Accelerate HIV Progress,” underscores the importance of collaboration to overcome this health challenge. [Left to Right] Andrea Halverson, USAID Health Office Director;...

by PRNewswire

https://techpapersworld.com/wp-content/uploads/2024/12/Countertop-Workers-Exposed-1280x720.jpg

HealthcareCountertop Workers Exposed to Serious Lung Disease

Durable and attractive, engineered stone countertops are a popular feature in modern American kitchens, but the workers who build them are risking their health. A growing number of these countertop workers are developing silicosis, a serious and long-term lung disease, according to a study being presented today at the annual meeting of the Radiological Society of North America (RSNA). “This is a new and emerging epidemic, and we must increase awareness of this disease process so we can avoid...

by business wire

https://techpapersworld.com/wp-content/uploads/2024/12/Revelation-Biosciences-Inc.-Announces-1280x720.jpg

HealthcareRevelation Biosciences Inc. Announces FDA Acceptance of Gemini IND

Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the treatment of disease, announced today that the United States Food and Drug Administration (FDA) has accepted its investigational new drug (IND) application for Gemini. This game changing milestone allows the Company to initiate its US based Phase 1b clinical study to evaluate the potential of Gemini as a preconditioning treatment in...

Older Posts